What is Spiriva Respimat 1.25 mcg?
Spiriva Respimat 1.25 mcg is a tiotropium bromide inhalation product used for long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). It is delivered via the Respimat inhaler. [1]
Is “1.25 mcg” the same as Spiriva HandiHaler (18 mcg)?
No. Spiriva comes in different formulations and strengths depending on the device. Spiriva Respimat is labeled in mcg per actuation (like 1.25 mcg), while Spiriva HandiHaler is typically associated with different dosing (commonly 18 mcg) and a different inhaler device. [1]
How is Spiriva Respimat 1.25 mcg typically used (dose timing)?
The key practical point is that the Respimat version is dosed for maintenance therapy on a schedule set by the prescriber, using the Respimat inhaler technique. For exact dosing frequency for your specific product (and age group, if applicable), you should follow the package instructions or your clinician’s directions. [1]
What kind of medication is tiotropium (and how does it work)?
Tiotropium is a long-acting antimuscarinic agent (LAMA). It works by blocking muscarinic receptors in the airways to help keep them open for longer periods, which supports symptom control in COPD. [1]
What side effects do people ask about?
Common issues patients may ask about with tiotropium inhalers can include dry mouth and other inhalation-related effects. Seek medical advice urgently for signs of severe allergic reaction or worsening breathing symptoms. Side effects and warnings vary by product label, so it’s important to check the specific Spiriva Respimat prescribing information. [1]
Is there a generic or lower-cost option?
Drug pricing and availability depend on your country and the current status of patents/exclusivity. DrugPatentWatch.com tracks patent and exclusivity information that can help you research whether cheaper alternatives are expected or available for tiotropium Respimat products. [2]
Sources
- https://www.asthmaandlung.org.uk/conditions/copd/treatments/spiriva-respimat
- https://www.drugpatentwatch.com/